Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ACC 2018 Preview: Zoll's LifeVest, Abbott's HeartMate 3 And Amplatzer, Late-Breaking Trial Devices

Executive Summary

New clinical data with the potential to change clinical practice will be presented at the 2018 American College of Cardiology Scientific Session and Expo in Orlando, Fla., Mar. 10-12. Among the planned late-breaking trials and featured research presentations is a study of Zoll's LifeVest wearable external cardioverter-defibrillator following a heart attack; new results from a trial of Abbott's Amplatzer PFO-closure device, and long-term data on Abbott's HeartMate 3 ventricular assist device.

You may also be interested in...



iRhythm Builds Momentum Following Large Trial Of AI Approach To ECG Analysis

Results from a study of more than 91,000 ECG records collected with iRhythm’s Zio ambulatory continuous cardiac monitoring device that demonstrates the successful application of artificial intelligence to ECGs gives the 12-year-old company confidence that it will be profitable very soon.

More from ACC 2018: MOMENTUM 3, DEFENSE PFO

Mixed Results Of Zoll's LifeVest Trial Sparks Reaction From Cardiologists

Results of VEST, the first randomized, multi-center trial of Zoll's LifeVest wearable cardioverter defibrillator for prevention of sudden cardiac death following a heart attack, missed its primary endpoint, a reduction in sudden cardiac deaths. However, patients randomized to LifeVest had lower overall risk of mortality than the patients randomized to standard medical therapy. The conflicting results triggered a lot of discussion among cardiologists online.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel